Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly insulin shot could replace daily injections for diabetes

NCT ID NCT07658417

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This study looks at how well a new once-weekly insulin, called insulin icodec, works for people with type 2 diabetes who are switching from a daily insulin. Researchers will track blood sugar control, treatment satisfaction, and how well patients stick to the new regimen over about 30 weeks. The study involves 216 adults in China and aims to see if the weekly shot is a practical and effective option in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
insulin icodec (a once-weekly insulin injection)
What this could lead to
If successful, this could show that a once-weekly insulin is as effective as daily insulin for managing type 2 diabetes, potentially simplifying treatment and improving quality of life.
What could go wrong
This is an early real-world study with only 216 participants and no comparison group, so results may not apply broadly. There is also a risk of hypoglycemia or other side effects with any insulin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 216 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult participants (≥18 years) with type 2 diabetes who have been diagnosed for at least one year and are currently being treated with once- or twice-daily basal insulin. The study includes approximately 216 participants across multiple centres in Canada, Italy, and China, reflecting a real-world population of individuals with type 2 diabetes receiving standard clinical care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to protocol). 2. The decision to initiate treatment with commercially available insulin icodec has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include participant in this study. 3. Male or female, age above or equal to 18 years at the time of signing informed consent. 4. Diagnosed with T2D greater than or equal to (≥) 1 year before signing informed consent. 5. Treated with once- or twice-daily basal insulin injections ≥ 6 months before signing informed consent. Any other antidiabetic medications are allowed, except for bolus insulin during the 90 days prior to switching to icodec for a period of 14 days or more. 6. Available glycated haemoglobin (HbA1c) within 90 days prior to the 'Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Initiation visit' (V1) if in line with local clinical practice. 7. Treatment-naïve to once-weekly insulin prior to the 'Initiation Visit' (V1) Exclusion Criteria: 1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Treatment with any investigational drug within 30 days prior to enrolment into study. 3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Hospital

    Beijing, Beijing Municipality, 100730, China

  • Gansu Provincial People's Hospital

    Lanzhou, Gansu, 730000, China

  • Hebei PetroChina Central Hospital

    Langfang, Hebi, 065099, China

  • Heilongjiang Provincial Hospital

    Harbin, Heilongjiang, 150036, China

  • NIS-Huai'an First People's Hospital-Endocrinology

    Huai'an, Jiangsu, 223300, China

  • NIS-Nanjing Jiangning Hospital-Endocrinology

    Nanjing, Jiangsu, 211199, China

  • Shandong Provincial Hospital

    Jinan, Shandong, 250098, China

  • Shiyan City People's Hospital

    Shiyan, Hubei, 442099, China

  • The Fifth People's Hospital of Shenyang

    Shenyang, Liaoning, 110023, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Urumuqi, Xinjiang, 830054, China

  • The People's Hospital of JiangMen

    Jiangmen, Guangdong, 529020, China

  • The Second Affiliated Hospital of Chongqing Medical University-Endocrinology

    Chongqing, Chongqing Municipality, 400010, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215004, China

  • Tongren Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200050, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.